Health Care
Commentary
Lousy Medicare Insurance Is Worsening Outcomes For All Patients
Medicare’s long-term financial outlook is in dire straits. While spending is already historically high, the Congressional Budget Office (CBO) projects that, without fundamental reform, things will only get worse. According to the CBO, total government spending will grow from 23.3% of GDP in 2025 to 26.6% in 2055. Almost two-thirds ...
Commentary
How Obamacare Set In Motion Today’s Premium Crisis
Democrats are panicking about a looming 75% average increase in the out-of-pocket cost of insurance premiums next year for the roughly 6% of the population that shops for coverage on Obamacare’s exchanges. Their panic led them to shut down the government at the end of September. The increase is a ...
Commentary
Trump Delivers Mixed Results on Health Reform
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure. But the results of his efforts to date have been mixed. Consider Trump’s approach to prescription drug prices. ...
Health Care
Dr. Wayne Winegarden – Competition is Key to Affordable, High-Quality Health Care
This week, Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, joins us to discuss his new brief exploring how forthcoming restrictions in a state program serving dual-eligible Medicare and Medi-Cal enrollees will hurt patients. He discusses how the movement in government both in California and nationally ...
Commentary
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Commentary
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Blog
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
Commentary
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
Commentary
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
Drug Prices
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
Lousy Medicare Insurance Is Worsening Outcomes For All Patients
Medicare’s long-term financial outlook is in dire straits. While spending is already historically high, the Congressional Budget Office (CBO) projects that, without fundamental reform, things will only get worse. According to the CBO, total government spending will grow from 23.3% of GDP in 2025 to 26.6% in 2055. Almost two-thirds ...
How Obamacare Set In Motion Today’s Premium Crisis
Democrats are panicking about a looming 75% average increase in the out-of-pocket cost of insurance premiums next year for the roughly 6% of the population that shops for coverage on Obamacare’s exchanges. Their panic led them to shut down the government at the end of September. The increase is a ...
Trump Delivers Mixed Results on Health Reform
Since taking office in January, President Trump has wasted little time advancing health policies he hopes will lower costs, improve quality, and promote innovation. Those are goals worth supporting, to be sure. But the results of his efforts to date have been mixed. Consider Trump’s approach to prescription drug prices. ...
Dr. Wayne Winegarden – Competition is Key to Affordable, High-Quality Health Care
This week, Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, joins us to discuss his new brief exploring how forthcoming restrictions in a state program serving dual-eligible Medicare and Medi-Cal enrollees will hurt patients. He discusses how the movement in government both in California and nationally ...
Patients Can’t Wait for Federal Action on Knock-Off Medicines
For millions of Americans, the new class of GLP-1 weight-loss drugs are as close to a miracle as modern medicine gets. Sold under brand names like Wegovy and Zepbound, these drugs have proven astoundingly successful at helping patients shed pounds. Unfortunately, a number of unscrupulous companies have sought to capitalize ...
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
